Navigation Links
Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma

  • 12 of 13 Total Evaluable Patients with Advanced B Cell Malignancies Had Complete Remissions (8 Patients) or Partial Remissions (4 Patients) Resulting in a 92% Objective Response Rate

  • 4 of 7 Evaluable Patients with Chemotherapy-Refractory Diffuse Large B-cell Lymphoma (DLBCL) Achieved Complete Remissions, 3 of Which Are Ongoing and 1 of Which Is Ongoing after 22 Months

  • The Results Have Been Published in the August 25, 2014 Issue of the American Society of Clinical Oncology's (ASCO) Journal of Clinical Oncology

  • The Results Support Kite's Plan to File an Investigational New Drug Application (IND) in the Fourth Quarter of 2014 to Initiate a Clinical Trial of Kite's Lead CAR-Based Product Candidate, KTE-C19, in Patients with DLBCL

Santa Monica, CA August 25, 2014 Kite Pharma, Inc., (NASDAQ: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months. These findings are being published in an article titled, "Chemotherapy-refractory Diffuse Large B-cell Lymphoma and Indolent B-cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor," DOI: 10.1200/JCO.2014.56.2025, which is appearing in the August 25, 2014 issue of the American Society of Clinical Oncology's Journal of Clinical Oncology.

Kite and the Surgery Branch of the NCI, led by Steven A. Rosenberg, M.D., Ph.D., are collaborating under a Cooperative Research and Development Agreement (CRADA) for the research and development of eACT based product candidates for the treatment of multiple cancer indications. The reported Phase 1-2a clinical trial is being conducted at the NCI with Dr. Rosenberg serving as principal investigator. Additional authors of the published study include James N. Kochenderfer, M.D., who presented earlier data for the NCI from the trial at the 55th American Society of Hematology (ASH) Annual Meeting in December 2013.

David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and Development, and Chief Medical Officer, commented, "To date, Kite and the NCI have conducted an extensive program to investigate personalized T cell immunotherapies for blood cancers and solid tumors, including in patients with refractory DLBCL. Both the high overall response rate and the durability of the complete remissions are noteworthy, and we believe our anti-CD19-CAR T cell approach holds great potential for the treatment of B cell malignancies, including those with aggressive, resistant disease for which there are no viable treatment options."

Ronald Levy, M.D., Professor of Medicine, Director of the Lymphoma Program and Former Chief of the Division of Oncology at Stanford University and member of Kite's Scientific Advisory Board, commented, "I have been impressed by the results reported and updated from Dr. Rosenberg's group at the NCI. Particularly compelling are the frequency and the duration of the responses obtained in the difficult-to-treat patient population with relapsed, refractory lymphomas." Dr. Levy serves as a consultant to Kite and is helping to guide the Company in their upcoming clinical trials.

"We are greatly encouraged by the strong results we have seen from our joint lead clinical program with the NCI," commented Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer. "Based on this substantial progress, Kite plans to file an IND in the fourth quarter of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015."

Key Study Findings

The published clinical trial results relate to patients in the second cohort in the NCI's Phase 1-2a clinical trial of anti-CD19 CAR T cell therapy. The second cohort consists of 15 patients, including two retreated patients from a prior cohort, with advanced B cell malignancies, of which 13 were evaluable for responses, including seven with chemotherapy-refractory DLBCL.

Patients received a conditioning regimen of chemotherapy (cyclophosphamide and fludarabine) followed one day later by a single infusion of anti-CD19-CAR T cells. The CAR-expressing T cells were produced from each patient's own peripheral blood mononuclear cells (PBMCs), modified using a gammaretroviral vector encoding the CAR, as well as a CD28 costimulatory moiety.

Of the seven evaluable chemotherapy-refractory DLBCL patients, six showed a response (four complete remissions and two partial remissions), and one had stable disease.

Duration of ongoing complete responses ranged from 9 to 22 months in patients with chemotherapy-refractory DLBCL and from 11 to 23 months in the patients with either chronic lymphocytic leukemia (CLL) or indolent lymphoma. Pursuant to the study protocol, patients are continuing to be monitored for duration of response. Updated results will be reported at the appropriate peer-reviewed forum.

Summary of Efficacy Findings:

Disease (Evaluable Patients) Complete Remission (CR) Partial Remission
7 Chemotherapy-refractory DLBCL(1) 4 Patients (3 patients with duration of ongoing CR from 9 to 22 months) 2 Patients
4 CLL 3 Patients (duration of ongoing CR from 14 to 23 months) 1 Patient
2 Indolent Lymphomas 1 Patient (duration of ongoing CR 11 months) 1 Patient

(1) Includes one patient with DLBCL that transformed from chronic lymphocytic leukemia, and three patients with primary mediastinal B cell lymphoma, a subtype of DLBCL.

As seen in other studies, infusion of anti-CD19 CAR T cells was associated with significant, acute toxicities, including fever, low blood pressure, focal neurological deficits, and delirium.


Contact: Justin Jackson
212-213-0006 x327
Burns McClellan

Related medicine news :

1. Seamless Medical Systems Announces the Launch of SNAP Express Rx™ to Enhance Pharmacy Patient Engagement and Clinical Care Coordination
2. The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins
3. Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy
4. MedX Pharmacy Helps with Back to School Preparation
5. RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies
6. College of Pharmacy Has Banner Research Awards Year
7. Poland Pharmaceutical Industry Worth $15 Billion by 2020 Says a New Report Available at
8. Good Neighbor Pharmacy Invites Patients to Share Their "Good Neighbor Story"
9. Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia's Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program
10. Global Egg Phosphatidylcholine Market by Application (Cosmetic, Pharmaceutical, Dietary Supplements) is Expected to Reach USD 12.2 Million by 2020
11. Kirby Lester Pharmacy Robot Users: 97% Report Improved Operating Efficiency
Post Your Comments:
(Date:11/27/2015)... ... , ... According to an article published November 15th by ABC ... security in light of the recent terrorist attacks in Paris, other cities are taking ... attack from reaching U.S. soil. Especially around special events that may be high-profile in ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... how filthy the toilets were," said an inventor from Hillside, N.J. "Many people ... improved seat cover so that individuals will always be protected from germs." , ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and ... Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa ... Sepsis conditions present in similar ways and require time-critical intervention to avoid large area ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... 2015  The total global healthcare industry is expected to ... Latin America has the highest projected growth ... Japan ), is second with growth projected at ... increased healthcare expenditure. In 2013-2014, total government funded healthcare was ... 2008-2009 to 41.2% in 2013-2014. In real terms, out of ...
Breaking Medicine Technology: